Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Fenk, Roland
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Goldschmidt H
,
Mai EK
,
Bertsch U
,
Fenk R
,
Nievergall E
,
Tichy D
,
Besemer B
,
Dürig J
,
Schroers R
,
von Metzler I
, et al.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase
. Lancet Haematol. 2022;9(11):e810-e821.
PubMed
Google Scholar
E
Mai EK
,
Goldschmid H
,
Miah K
,
Bertsch U
,
Besemer B
,
Hänel M
,
Krzykalla J
,
Fenk R
,
Schlenzka J
,
Munder M
, et al.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol. 2024;11(2):e101-e113.
PubMed
Google Scholar
G
Maura F
,
Rajanna ARaj
,
Ziccheddu B
,
Poos AM
,
Derkach A
,
Maclachlan K
,
Durante M
,
Diamond B
,
Papadimitriou M
,
Davies F
, et al.
Genomic Classification and Individualized Prognosis in Multiple Myeloma.
J Clin Oncol. 2024:JCO2301277.
PubMed
Google Scholar
I
Gagelmann N
,
Eikema D-J
,
Koster L
,
Netelenbos T
,
McDonald A
,
Stoppa A-M
,
Fenk R
,
Anagnostopoulos A
,
van Gorkom G
,
Deconinck E
, et al.
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Eur J Haematol. 2023.
PubMed
Google Scholar
L
Garderet L
,
Gras L
,
Koster L
,
de Wreede L
,
Montserrat R
,
Vincent L
,
Fenk R
,
Karunanithi K
,
Deeren D
,
Kaufmann M
, et al.
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow
. Haematologica. 2024.
PubMed
Google Scholar
P
Metselaar J
,
Lammers T
,
Boquoi A
,
Fenk R
,
Testaquadra F
,
Schemionek M
,
Kiessling F
,
Isfort S
,
Wilop S
,
Crysandt M
.
A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma.
Drug Deliv Transl Res. 2023.
PubMed
Google Scholar
T
Gagelmann N
,
Eikema D-J
,
Koster L
,
Caillot D
,
Pioltelli P
,
Lleonart JBargay
,
Reményi P
,
Blaise D
,
Schaap N
,
Trneny M
, et al.
Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT.
Biol Blood Marrow Transplant. 2019.
PubMed
Google Scholar